Invent: Life Sciences

In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a source of considerable investment for the pharmaceutical sector, we are only just starting to see its impact for therapy developers. A 2024 report from McKinsey Glo

In this episode, host Stuart explores what the sustainability goals of Big Pharma mean for those organisations, and the companies that support them. With insights from Ryan Walker, Sustainability Program Leader at Cytiva, and Wenshu Xu, Drug Discovery Tools Team Lead at TTP, we review the progress made by the industry so far and some examples where innovative thinking has had an im

In this two-part series, host Stuart Lowe examines two factors testing the resilience of the biopharma industry. As society simultaneously navigates a green transition alongside an AI revolution, so the biopharma industry faces mounting pressure to address its carbon emissions, deploy cutting-edge digital technology, while streamlining operations. Along with his guests, discover th

In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of

The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fun

Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP. With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this series, we’ll be looking at the people, processes and partnerships we’ll need to

Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry. We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future of genetic research. A big thank you to all our guests that featured in this series, m

Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and products themselves are characterised. So, do current process analytical tools provide t

Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the playbook in terms of sourcing cellular material for advanced therapies manufacture. So how might therapy developers benefit from the unique abilities of stem cells?

Throughout almost all of medical history, it was assumed that the average white male response to drug trials could be extrapolated to all potential recipients. But when we look at the poorer health outcomes for women and minorities, could the underlying assumptions in medical research be a contributing factor? If so, what is being done to solve them?To find out, join us on Invent: